-
![SUBSTITUTED-6,8-DIOXABICYCLO[3.2.1]OCTANE-2,3-DIOL COMPOUNDS AS TARGETING AGENTS OF ASGPR](/abs-image/US/2019/10/24/US20190321382A1/abs.jpg.150x150.jpg)
1.发明申请公开(公告)号：US20190321382A1
公开(公告)日：2019-10-24
申请号：US16450649
申请日：2019-06-24
Applicant: Pfizer Inc.
Inventor： Spiros Liras , Vincent Mascitti , Benjamin Thuma
IPC: A61K31/706 , C07D309/14 , A61K47/64 , A61K31/7008 , C07H15/12 , C07D493/08 , C07H15/26 , C07H13/04 , C07K5/065 , A61K31/7056 , A61K38/46 , C07H15/08
Abstract: Compounds of Formula (A) are described herein and the uses thereof for the treatment of diseases, conditions and/or disorders mediated by pharmaceutical compositions and the uses thereof as asialoglycoprotein receptor (ASGPR) targeting agents.
-
![SUBSTITUTED 3-AZABICYCLO[3.1.0]HEXANES AS KETOHEXOKINASE INHIBITORS](/abs-image/US/2020/12/03/US20200377482A1/abs.jpg.150x150.jpg)
公开(公告)号：US20200377482A1
公开(公告)日：2020-12-03
申请号：US16999295
申请日：2020-08-21
Applicant: Pfizer Inc.
Inventor： Matthew Dowling , Dilinie Fernando , Kentaro Futatsugi , Kim Huard , Thomas Victor Magee , Brian Raymer , Andre Shavnya , Aaron Smith , Benjamin Thuma , Andy Tsai , Meihua Tu
IPC: C07D403/14 , A61K31/403 , C07D401/04 , C07D401/14 , C07D403/04
Abstract: Provided herein are substituted 3-azabicyclo[3.1.0]hexanes as ketohexokinase inhibitors, processes to make said compounds, and methods comprising administering said compounds to a mammal in need thereof.
-
![Substituted-6,8-dioxabicyclo[3.2.1]octane-2,3-diol compounds as targeting agents of ASGPR](/abs-image/US/2017/04/11/US09617293B2/abs.jpg.150x150.jpg)
3.发明授权公开(公告)号：US09617293B2
公开(公告)日：2017-04-11
申请号：US15093178
申请日：2016-04-07
Applicant: Pfizer Inc.
Inventor： Spiros Liras , Vincent Mascitti , Benjamin Thuma
IPC: C07D493/08 , A61K31/35 , C07H15/08 , C07D309/14 , C07H13/04 , C07H15/26 , A61K31/7008 , A61K31/7056 , A61K31/706 , A61K38/46 , C07H15/12 , C07K5/065
CPC classification number: A61K31/706 , A61K31/7008 , A61K31/7056 , A61K38/465 , A61K47/64 , C07D309/14 , C07D493/08 , C07H13/04 , C07H15/08 , C07H15/12 , C07H15/26 , C07K5/06078 , C12Y301/00 , Y02A50/463
Abstract: Compounds of Formula (A) are described herein and the uses thereof for the treatment of diseases, conditions and/or disorders mediated by pharmaceutical compositions and the uses thereof as asialoglycoprotein receptor (ASGPR) targeting agents.
-
![SUBSTITUTED-6,8-DIOXABICYCLO[3.2.1]OCTANE-2,3-DIOL COMPOUNDS AS TARGETING AGENTS OF ASGPR](/abs-image/US/2015/11/19/US20150329555A1/abs.jpg.150x150.jpg)
4.发明申请SUBSTITUTED-6,8-DIOXABICYCLO[3.2.1]OCTANE-2,3-DIOL COMPOUNDS AS TARGETING AGENTS OF ASGPR 审中-公开取代的6,8-二氧杂环戊烯[3.2.1]作为ASGPR的靶向剂的OCT-2,3-DIOL化合物公开(公告)号：US20150329555A1
公开(公告)日：2015-11-19
申请号：US14714484
申请日：2015-05-18
Applicant: Pfizer Inc.
Inventor： Spiros Liras , Vincent Mascitti , Benjamin Thuma
IPC: C07D493/08 , C07D309/14
CPC classification number: A61K31/706 , A61K31/7008 , A61K31/7056 , A61K38/465 , A61K47/64 , C07D309/14 , C07D493/08 , C07H13/04 , C07H15/08 , C07H15/12 , C07H15/26 , C07K5/06078 , C12Y301/00 , Y02A50/463
Abstract: Compounds of Formula (A) are described herein and the uses thereof for the treatment of diseases, conditions and/or disorders mediated by pharmaceutical compositions and the uses thereof as asialoglycoprotein receptor (ASGPR) targeting agents.
Abstract translation: 本文描述了式（A）的化合物及其用于治疗由药物组合物介导的疾病，病症和/或病症及其作为唾液酸糖蛋白受体（ASGPR）靶向剂的用途的用途。
-
![Substituted 3-azabicyclo[3.1.0]hexanes as ketohexokinase inhibitors](/abs-image/US/2023/04/25/US11634410B2/abs.jpg.150x150.jpg)
公开(公告)号：US11634410B2
公开(公告)日：2023-04-25
申请号：US17209780
申请日：2021-03-23
Applicant: Pfizer Inc.
Inventor： Matthew Dowling , Dilinie Fernando , Kentaro Futatsugi , Kim Huard , Thomas Victor Magee , Brian Raymer , Andre Shavnya , Aaron Smith , Benjamin Thuma , Andy Tsai , Meihua Tu
IPC: C07D403/14 , A61K31/403 , C07D401/04 , C07D401/14 , C07D403/04
Abstract: Provided herein are substituted 3-azabicyclo[3.1.0]hexanes as ketohexokinase inhibitors, processes to make said compounds, and methods comprising administering said compounds to a mammal in need thereof.
-
Patent Agency Ranking
![SUBSTITUTED 3-AZABICYCLO[3.1.0]HEXANES AS KETOHEXOKINASE INHIBITORS](/abs-image/US/2021/10/07/US20210309644A1/abs.jpg.150x150.jpg)
公开(公告)号：US20210309644A1
公开(公告)日：2021-10-07
申请号：US17209780
申请日：2021-03-23
Applicant: Pfizer Inc.
Inventor： Matthew Dowling , Dilinie Fernando , Kentaro Futatsugi , Kim Huard , Thomas Victor Magee , Brian Raymer , Andre Shavnya , Aaron Smith , Benjamin Thuma , Andy Tsai , Meihua Tu
IPC: C07D403/14 , A61K31/403 , C07D401/04 , C07D401/14 , C07D403/04
Abstract: Provided herein are substituted 3-azabicyclo[3.1.0]hexanes as ketohexokinase inhibitors, processes to make said compounds, and methods comprising administering said compounds to a mammal in need thereof.
-
![Substituted-6,8-dioxabicyclo[3.2.1]octane-2,3-diol compounds as targeting agents of ASGPR](/abs-image/US/2019/08/13/US10376531B2/abs.jpg.150x150.jpg)
7.发明授权公开(公告)号：US10376531B2
公开(公告)日：2019-08-13
申请号：US16023232
申请日：2018-06-29
Applicant: Pfizer Inc.
Inventor： Spiros Liras , Vincent Mascitti , Benjamin Thuma
IPC: C07D493/08 , A61K31/357 , A61K31/706 , C07D309/14 , C07H13/04 , C07H15/26 , A61K31/7008 , A61K31/7056 , A61K38/46 , C07H15/08 , C07H15/12 , C07K5/065 , A61K47/64
Abstract: Compounds of Formula (A) are described herein and the uses thereof for the treatment of diseases, conditions and/or disorders mediated by pharmaceutical compositions and the uses thereof as asialoglycoprotein receptor (ASGPR) targeting agents.
-
![SUBSTITUTED 3-AZABICYCLO[3.1.0]HEXANES AS KETOHEXOKINASE INHIBITORS](/abs-image/US/2019/04/11/US20190106412A1/abs.jpg.150x150.jpg)
公开(公告)号：US20190106412A1
公开(公告)日：2019-04-11
申请号：US16211283
申请日：2018-12-06
Applicant: Pfizer Inc.
Inventor： Matthew Dowling , Dilinie Fernando , Kentaro Futatsugi , Kim Huard , Thomas Victor Magee , Brian Raymer , Andre Shavnya , Aaron Smith , Benjamin Thuma , Andy Tsai , Meihua Tu
IPC: C07D403/14 , C07D403/04 , A61K31/403 , C07D401/04 , C07D401/14
Abstract: Provided herein are substituted 3-azabicyclo[3.1.0]hexanes as ketohexokinase inhibitors, processes to make said compounds, and methods comprising administering said compounds to a mammal in need thereof.
-
![SUBSTITUTED-6,8-DIOXABICYCLO[3.2.1]OCTANE-2,3-DIOL COMPOUNDS AS TARGETING AGENTS OF ASGPR](/abs-image/US/2018/10/18/US20180296585A1/abs.jpg.150x150.jpg)
9.发明申请公开(公告)号：US20180296585A1
公开(公告)日：2018-10-18
申请号：US16023232
申请日：2018-06-29
Applicant: Pfizer Inc.
Inventor： Spiros Liras , Vincent Mascitti , Benjamin Thuma
IPC: A61K31/706 , C07D309/14 , A61K47/64 , C07D493/08 , C07H15/26 , C07H13/04 , C07K5/065 , A61K31/7056 , A61K38/46 , C07H15/08 , C07H15/12 , A61K31/7008
CPC classification number: A61K31/706 , A61K31/7008 , A61K31/7056 , A61K38/465 , A61K47/64 , C07D309/14 , C07D493/08 , C07H13/04 , C07H15/08 , C07H15/12 , C07H15/26 , C07K5/06078 , C12Y301/00 , Y02A50/463
Abstract: Compounds of Formula (A) are described herein and the uses thereof for the treatment of diseases, conditions and/or disorders mediated by pharmaceutical compositions and the uses thereof as asialoglycoprotein receptor (ASGPR) targeting agents.
-
![Substituted-6,8-dioxabicyclo[3.2.1]octane-2,3-diol compounds as targeting agents of ASGPR](/abs-image/US/2020/10/27/US10813942B2/abs.jpg.150x150.jpg)
10.发明授权公开(公告)号：US10813942B2
公开(公告)日：2020-10-27
申请号：US16450649
申请日：2019-06-24
Applicant: Pfizer Inc.
Inventor： Spiros Liras , Vincent Mascitti , Benjamin Thuma
IPC: C07D493/08 , A61K31/357 , A61K31/706 , C07D309/14 , C07H13/04 , C07H15/26 , A61K47/64 , A61K31/7008 , A61K31/7056 , A61K38/46 , C07H15/08 , C07H15/12 , C07K5/065
Abstract: Compounds of Formula (A) are described herein and the uses thereof for the treatment of diseases, conditions and/or disorders mediated by pharmaceutical compositions and the uses thereof as asialoglycoprotein receptor (ASGPR) targeting agents.
-
-
-
-
-
-
-
-
-
Search Results
21
records
(took 0.03 seconds)
